Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Structure, Molecular Modeling, and Function of the Novel Potassium Channel Blocker Urotoxin Isolated from the Venom of the Australian Scorpion Urodacus yaschenkoi

Karen Luna-Ramírez, Adam Bartok, Rita Restano-Cassulini, Veronica Quintero-Hernández, Fredy I. V. Coronas, Janni Christensen, Christine E. Wright, Gyorgy Panyi and Lourival D. Possani
Molecular Pharmacology July 2014, 86 (1) 28-41; DOI: https://doi.org/10.1124/mol.113.090183
Karen Luna-Ramírez
Australian Venom Research Unit and Cardiovascular Therapeutics Unit, Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria, Australia (K.L.-R., C.E.W.); Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Avenida Universidad, Cuernavaca, Mexico (R.R.-C., V.Q.-H., F.I.V.C., L.D.P.); Department of Biophysics and Cell Biology, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary (A.B., G.P.); MTA-DE Cell Biology and Signaling Research Group, Debrecen, Hungary (G.P.); and Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia (J.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam Bartok
Australian Venom Research Unit and Cardiovascular Therapeutics Unit, Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria, Australia (K.L.-R., C.E.W.); Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Avenida Universidad, Cuernavaca, Mexico (R.R.-C., V.Q.-H., F.I.V.C., L.D.P.); Department of Biophysics and Cell Biology, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary (A.B., G.P.); MTA-DE Cell Biology and Signaling Research Group, Debrecen, Hungary (G.P.); and Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia (J.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rita Restano-Cassulini
Australian Venom Research Unit and Cardiovascular Therapeutics Unit, Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria, Australia (K.L.-R., C.E.W.); Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Avenida Universidad, Cuernavaca, Mexico (R.R.-C., V.Q.-H., F.I.V.C., L.D.P.); Department of Biophysics and Cell Biology, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary (A.B., G.P.); MTA-DE Cell Biology and Signaling Research Group, Debrecen, Hungary (G.P.); and Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia (J.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Veronica Quintero-Hernández
Australian Venom Research Unit and Cardiovascular Therapeutics Unit, Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria, Australia (K.L.-R., C.E.W.); Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Avenida Universidad, Cuernavaca, Mexico (R.R.-C., V.Q.-H., F.I.V.C., L.D.P.); Department of Biophysics and Cell Biology, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary (A.B., G.P.); MTA-DE Cell Biology and Signaling Research Group, Debrecen, Hungary (G.P.); and Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia (J.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fredy I. V. Coronas
Australian Venom Research Unit and Cardiovascular Therapeutics Unit, Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria, Australia (K.L.-R., C.E.W.); Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Avenida Universidad, Cuernavaca, Mexico (R.R.-C., V.Q.-H., F.I.V.C., L.D.P.); Department of Biophysics and Cell Biology, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary (A.B., G.P.); MTA-DE Cell Biology and Signaling Research Group, Debrecen, Hungary (G.P.); and Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia (J.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janni Christensen
Australian Venom Research Unit and Cardiovascular Therapeutics Unit, Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria, Australia (K.L.-R., C.E.W.); Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Avenida Universidad, Cuernavaca, Mexico (R.R.-C., V.Q.-H., F.I.V.C., L.D.P.); Department of Biophysics and Cell Biology, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary (A.B., G.P.); MTA-DE Cell Biology and Signaling Research Group, Debrecen, Hungary (G.P.); and Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia (J.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine E. Wright
Australian Venom Research Unit and Cardiovascular Therapeutics Unit, Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria, Australia (K.L.-R., C.E.W.); Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Avenida Universidad, Cuernavaca, Mexico (R.R.-C., V.Q.-H., F.I.V.C., L.D.P.); Department of Biophysics and Cell Biology, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary (A.B., G.P.); MTA-DE Cell Biology and Signaling Research Group, Debrecen, Hungary (G.P.); and Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia (J.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gyorgy Panyi
Australian Venom Research Unit and Cardiovascular Therapeutics Unit, Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria, Australia (K.L.-R., C.E.W.); Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Avenida Universidad, Cuernavaca, Mexico (R.R.-C., V.Q.-H., F.I.V.C., L.D.P.); Department of Biophysics and Cell Biology, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary (A.B., G.P.); MTA-DE Cell Biology and Signaling Research Group, Debrecen, Hungary (G.P.); and Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia (J.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lourival D. Possani
Australian Venom Research Unit and Cardiovascular Therapeutics Unit, Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria, Australia (K.L.-R., C.E.W.); Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Avenida Universidad, Cuernavaca, Mexico (R.R.-C., V.Q.-H., F.I.V.C., L.D.P.); Department of Biophysics and Cell Biology, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary (A.B., G.P.); MTA-DE Cell Biology and Signaling Research Group, Debrecen, Hungary (G.P.); and Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia (J.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

This communication reports the structural and functional characterization of urotoxin, the first K+ channel toxin isolated from the venom of the Australian scorpion Urodacus yaschenkoi. It is a basic peptide consisting of 37 amino acids with an amidated C-terminal residue. Urotoxin contains eight cysteines forming four disulfide bridges with sequence similarities resembling the α-potassium channel toxin 6 (α-KTx-6) subfamily of peptides; it was assigned the systematic number of α-KTx-6.21. Urotoxin is a potent blocker of human voltage-gated potassium channel (Kv)1.2 channels, with an IC50 of 160 pM, whereas its affinity for other channels tested was in the nanomolar range (hKv1.1, IC50 = 253 nM; hKv1.3, IC50 = 91 nM; and hKCa3.1, IC50 = 70 nM). The toxin had no effect on hKv1.4, hKv1.5, human ether-à-go-go–related gene type 1 (hERG1), or human ether-à-go-go–like (hELK2) channels. Multiple sequence alignments from the venom gland transcriptome showed the existence of four other new peptides similar to urotoxin. Computer modeling of urotoxin’s three-dimensional structure suggests the presence of the α/β-scaffold characteristic of other scorpion toxins, although very likely forming an uncommon disulfide pairing pattern. Using molecular dynamics, a model for the binding of this peptide to human Kv1.2 and hKv1.1 channels is presented, along with the binding of an in silico mutant urotoxin (Lys25Ala) to both channels. Urotoxin enriches our knowledge of K+ channel toxins and, due to its high affinity for hKv1.2 channels, it may be a good candidate for the development of pharmacologic tools to study the physiologic functions of K+ channels or related channelopathies and for restoring axonal conduction in demyelinated axons.

Footnotes

    • Received October 8, 2013.
    • Accepted April 10, 2014.
  • This work was supported by grants from the Dirección General de Asuntos del Personal Academico, UNAM [IN200113-3]; the Struan Sutherland Fund, AVRU, Department of Pharmacology and Therapeutics, University of Melbourne; a scholarship from CONACyT and from the Hugh Williamson Foundation, through the Museum Victoria; the European Union, and the State of Hungary, cofinanced by the European Social Fund in the framework of the National Excellence Program [TÁMOP 4.2.4. A/2-11-1-2012-0001] and [TÁMOP 4.2.2-A-11/1/KONV-2012-0025]; and the State of Hungary [OTKA K 75904] and [OTKA NK 101337]. The three-dimensional computer model of urotoxin and the brute force dynamic simulation was supported by a Victorian Life Sciences Computation Initiative (VLSCI) grant number [VR0064] at its Peak Computing Facility at the University of Melbourne, an initiative of the Victorian Government, Australia.

  • dx.doi.org/10.1124/mol.113.090183.

  • ↵Embedded ImageThis article has supplemental material available at molpharm.aspetjournals.org.

  • Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 86 (1)
Molecular Pharmacology
Vol. 86, Issue 1
1 Jul 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Structure, Molecular Modeling, and Function of the Novel Potassium Channel Blocker Urotoxin Isolated from the Venom of the Australian Scorpion Urodacus yaschenkoi
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Characterization of the Potassium Channel Blocker Urotoxin

Karen Luna-Ramírez, Adam Bartok, Rita Restano-Cassulini, Veronica Quintero-Hernández, Fredy I. V. Coronas, Janni Christensen, Christine E. Wright, Gyorgy Panyi and Lourival D. Possani
Molecular Pharmacology July 1, 2014, 86 (1) 28-41; DOI: https://doi.org/10.1124/mol.113.090183

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Characterization of the Potassium Channel Blocker Urotoxin

Karen Luna-Ramírez, Adam Bartok, Rita Restano-Cassulini, Veronica Quintero-Hernández, Fredy I. V. Coronas, Janni Christensen, Christine E. Wright, Gyorgy Panyi and Lourival D. Possani
Molecular Pharmacology July 1, 2014, 86 (1) 28-41; DOI: https://doi.org/10.1124/mol.113.090183
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The binding site for KCI807 in the androgen receptor
  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics